Incidence of tuberculosis infection in spondyloarthritis patients treated with biological and conventional diseasemodifying anti-rheumatic drugs in an endemic area
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/213715 |
Resumo: | Introduction: Registries of spondyloarthritis (SpA) patients’ follow-up provided evidence that tumor necrosis factor inhibitors (TNFi) increase the incidence of active tuberculosis infection (TB). However, most of these registries are from low burden TB areas. Few studies evaluated the safety of biologic agents in TB endemic areas. This study compares the TB incidence rate (TB IR) in anti-TNF-naïve and anti-TNFexperienced subjects with SpA in a high TB incidence setting. Methods: In this retrospective cohort study, medical records from patients attending a SpA clinic during 13 years (2004 to 2016) in a university hospital were reviewed. The TB IR was calculated and expressed as number of events per 105 patients/year; the incidence rate ratio (IRR) associated with the use of TNFi was calculated. Results: A total of 277 patients, 173 anti-TNF-naïve and 104 anti-TNF-experienced subjects, were evaluated; 35.7% (N = 35) of patients who were prescribed an antiTNF drug were diagnosed with latent tuberculosis infection (LTBI). Total follow-up time (person-years) was 1667.8 for anti-TNF-naïve and 394.9 for anti-TNF-experienced patients. TB IR (95% CI) was 299.8 (37.4-562.2) for anti-TNF naïve and 1012.9 (25.3-2000.5) for anti-TNF experienced subjects. The IRR associated with the use of TNFi was 10.4 (2.3- 47.9). Conclusions: In this high TB incidence setting, SpA patients exposed to anti-TNF therapy had a higher incidence of TB compared to anti-TNF-naïve subjects, although the TB incidence in the control group was significant. |
id |
UFRGS-2_f68a66ac50a470609b6feb79d524c016 |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/213715 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Morsch, André Luís BittencourtHenrique, Lilian RodriguesSilva, Denise RossatoGarziera, GiovanaXavier, Ricardo MachadoHax, VanessaFerreira, Manoela FantinelKohem, Charles LubiancaMancuso, Aline Castello BrancoGasparin, Andrese AlineBrenol, Claiton ViegasAndrade, Nicole Pamplona Bueno deMenegat, Franciele de AlmeidaViecceli, DanielaBohn, RenataPalominos, Penelope Esther2020-09-24T04:00:58Z20202357-9730http://hdl.handle.net/10183/213715001116721Introduction: Registries of spondyloarthritis (SpA) patients’ follow-up provided evidence that tumor necrosis factor inhibitors (TNFi) increase the incidence of active tuberculosis infection (TB). However, most of these registries are from low burden TB areas. Few studies evaluated the safety of biologic agents in TB endemic areas. This study compares the TB incidence rate (TB IR) in anti-TNF-naïve and anti-TNFexperienced subjects with SpA in a high TB incidence setting. Methods: In this retrospective cohort study, medical records from patients attending a SpA clinic during 13 years (2004 to 2016) in a university hospital were reviewed. The TB IR was calculated and expressed as number of events per 105 patients/year; the incidence rate ratio (IRR) associated with the use of TNFi was calculated. Results: A total of 277 patients, 173 anti-TNF-naïve and 104 anti-TNF-experienced subjects, were evaluated; 35.7% (N = 35) of patients who were prescribed an antiTNF drug were diagnosed with latent tuberculosis infection (LTBI). Total follow-up time (person-years) was 1667.8 for anti-TNF-naïve and 394.9 for anti-TNF-experienced patients. TB IR (95% CI) was 299.8 (37.4-562.2) for anti-TNF naïve and 1012.9 (25.3-2000.5) for anti-TNF experienced subjects. The IRR associated with the use of TNFi was 10.4 (2.3- 47.9). Conclusions: In this high TB incidence setting, SpA patients exposed to anti-TNF therapy had a higher incidence of TB compared to anti-TNF-naïve subjects, although the TB incidence in the control group was significant.application/pdfengClinical and biomedical research. Vol. 40, n. 1 (2020), p. 1-6TuberculoseEspondilite anquilosanteInibidores do fator de necrose tumoralFator de necrose tumoral alfaIncidênciaSpondyloarthritisTuberculosisAnti-TNF therapyTumor necrosis factor alphaTuberculin skin testIncidence of tuberculosis infection in spondyloarthritis patients treated with biological and conventional diseasemodifying anti-rheumatic drugs in an endemic areainfo:eu-repo/semantics/articleinfo:eu-repo/semantics/otherinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001116721.pdf.txt001116721.pdf.txtExtracted Texttext/plain26028http://www.lume.ufrgs.br/bitstream/10183/213715/2/001116721.pdf.txtfd200fc67aee4622ac8b31ed2a85a072MD52ORIGINAL001116721.pdfTexto completo (inglês)application/pdf258219http://www.lume.ufrgs.br/bitstream/10183/213715/1/001116721.pdff0d63e7bfe488c18cd8ab8e532d8c158MD5110183/2137152020-09-25 04:03:35.909294oai:www.lume.ufrgs.br:10183/213715Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2020-09-25T07:03:35Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Incidence of tuberculosis infection in spondyloarthritis patients treated with biological and conventional diseasemodifying anti-rheumatic drugs in an endemic area |
title |
Incidence of tuberculosis infection in spondyloarthritis patients treated with biological and conventional diseasemodifying anti-rheumatic drugs in an endemic area |
spellingShingle |
Incidence of tuberculosis infection in spondyloarthritis patients treated with biological and conventional diseasemodifying anti-rheumatic drugs in an endemic area Morsch, André Luís Bittencourt Tuberculose Espondilite anquilosante Inibidores do fator de necrose tumoral Fator de necrose tumoral alfa Incidência Spondyloarthritis Tuberculosis Anti-TNF therapy Tumor necrosis factor alpha Tuberculin skin test |
title_short |
Incidence of tuberculosis infection in spondyloarthritis patients treated with biological and conventional diseasemodifying anti-rheumatic drugs in an endemic area |
title_full |
Incidence of tuberculosis infection in spondyloarthritis patients treated with biological and conventional diseasemodifying anti-rheumatic drugs in an endemic area |
title_fullStr |
Incidence of tuberculosis infection in spondyloarthritis patients treated with biological and conventional diseasemodifying anti-rheumatic drugs in an endemic area |
title_full_unstemmed |
Incidence of tuberculosis infection in spondyloarthritis patients treated with biological and conventional diseasemodifying anti-rheumatic drugs in an endemic area |
title_sort |
Incidence of tuberculosis infection in spondyloarthritis patients treated with biological and conventional diseasemodifying anti-rheumatic drugs in an endemic area |
author |
Morsch, André Luís Bittencourt |
author_facet |
Morsch, André Luís Bittencourt Henrique, Lilian Rodrigues Silva, Denise Rossato Garziera, Giovana Xavier, Ricardo Machado Hax, Vanessa Ferreira, Manoela Fantinel Kohem, Charles Lubianca Mancuso, Aline Castello Branco Gasparin, Andrese Aline Brenol, Claiton Viegas Andrade, Nicole Pamplona Bueno de Menegat, Franciele de Almeida Viecceli, Daniela Bohn, Renata Palominos, Penelope Esther |
author_role |
author |
author2 |
Henrique, Lilian Rodrigues Silva, Denise Rossato Garziera, Giovana Xavier, Ricardo Machado Hax, Vanessa Ferreira, Manoela Fantinel Kohem, Charles Lubianca Mancuso, Aline Castello Branco Gasparin, Andrese Aline Brenol, Claiton Viegas Andrade, Nicole Pamplona Bueno de Menegat, Franciele de Almeida Viecceli, Daniela Bohn, Renata Palominos, Penelope Esther |
author2_role |
author author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Morsch, André Luís Bittencourt Henrique, Lilian Rodrigues Silva, Denise Rossato Garziera, Giovana Xavier, Ricardo Machado Hax, Vanessa Ferreira, Manoela Fantinel Kohem, Charles Lubianca Mancuso, Aline Castello Branco Gasparin, Andrese Aline Brenol, Claiton Viegas Andrade, Nicole Pamplona Bueno de Menegat, Franciele de Almeida Viecceli, Daniela Bohn, Renata Palominos, Penelope Esther |
dc.subject.por.fl_str_mv |
Tuberculose Espondilite anquilosante Inibidores do fator de necrose tumoral Fator de necrose tumoral alfa Incidência |
topic |
Tuberculose Espondilite anquilosante Inibidores do fator de necrose tumoral Fator de necrose tumoral alfa Incidência Spondyloarthritis Tuberculosis Anti-TNF therapy Tumor necrosis factor alpha Tuberculin skin test |
dc.subject.eng.fl_str_mv |
Spondyloarthritis Tuberculosis Anti-TNF therapy Tumor necrosis factor alpha Tuberculin skin test |
description |
Introduction: Registries of spondyloarthritis (SpA) patients’ follow-up provided evidence that tumor necrosis factor inhibitors (TNFi) increase the incidence of active tuberculosis infection (TB). However, most of these registries are from low burden TB areas. Few studies evaluated the safety of biologic agents in TB endemic areas. This study compares the TB incidence rate (TB IR) in anti-TNF-naïve and anti-TNFexperienced subjects with SpA in a high TB incidence setting. Methods: In this retrospective cohort study, medical records from patients attending a SpA clinic during 13 years (2004 to 2016) in a university hospital were reviewed. The TB IR was calculated and expressed as number of events per 105 patients/year; the incidence rate ratio (IRR) associated with the use of TNFi was calculated. Results: A total of 277 patients, 173 anti-TNF-naïve and 104 anti-TNF-experienced subjects, were evaluated; 35.7% (N = 35) of patients who were prescribed an antiTNF drug were diagnosed with latent tuberculosis infection (LTBI). Total follow-up time (person-years) was 1667.8 for anti-TNF-naïve and 394.9 for anti-TNF-experienced patients. TB IR (95% CI) was 299.8 (37.4-562.2) for anti-TNF naïve and 1012.9 (25.3-2000.5) for anti-TNF experienced subjects. The IRR associated with the use of TNFi was 10.4 (2.3- 47.9). Conclusions: In this high TB incidence setting, SpA patients exposed to anti-TNF therapy had a higher incidence of TB compared to anti-TNF-naïve subjects, although the TB incidence in the control group was significant. |
publishDate |
2020 |
dc.date.accessioned.fl_str_mv |
2020-09-24T04:00:58Z |
dc.date.issued.fl_str_mv |
2020 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/other |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/213715 |
dc.identifier.issn.pt_BR.fl_str_mv |
2357-9730 |
dc.identifier.nrb.pt_BR.fl_str_mv |
001116721 |
identifier_str_mv |
2357-9730 001116721 |
url |
http://hdl.handle.net/10183/213715 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Clinical and biomedical research. Vol. 40, n. 1 (2020), p. 1-6 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/213715/2/001116721.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/213715/1/001116721.pdf |
bitstream.checksum.fl_str_mv |
fd200fc67aee4622ac8b31ed2a85a072 f0d63e7bfe488c18cd8ab8e532d8c158 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801224998096994304 |